48
Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol
Ther. 2006;23(5):617–28.- Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, et al. CDP571, a
humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn’s
disease: a randomised, double blind, placebo controlled trial. Gut. 2004;53(10):1485–93. - Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and func-
tional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther.
2002;301(2):418–26. - Banner DW, D’Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, et al. Crystal structure
of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF
receptor activation. Cell. 1993;73(3):431–45. - Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, et al. Soluble
tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotox-
emia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol.
1993;151(3):1548–61. - Levin AD, Wildenberg ME, van den Brink GR. Mechanism of action of anti-TNF therapy in
inflammatory bowel disease. J Crohns Colitis. 2016;10(8):989–97. - Jin JF, Zhu LL, Chen M, Xu HM, Wang HF, Feng XQ, et al. The optimal choice of medication
administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient
Prefer Adherence. 2015;9:923–42. - Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics.
J Pharm Sci. 2004;93(11):2645–68. - Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial
Transplant. 2005;20(Suppl 6):vi3–9.
B. P. Va u g h n